Legorreta Pablo G.

SEC source: 0001507678-26-000006 · wk-form4_1786137872.xml · derivative · entry 13

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 662,701

Underlying: Class A Ordinary Shares · 300,000 shares

Expires not disclosed

F2 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001507678-26-000006 · wk-form4_1786137872.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,307,820

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001193125-26-248221 · ownership.xml · derivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Class A Common Stock · 135,000 shares

Expires 2036-05-28

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0001507678-26-000004 · wk-form4_1778275033.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,242,604

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001507678-26-000002 · wk-form4_1771016624.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,098,783

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001507678-25-000010 · wk-form4_1762550365.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 940,955

F1 · acquired: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001802768-25-000105 · wk-form4_1754686796.xml · derivative · entry 13

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 692,701

Underlying: Class A Ordinary Shares · 600,000 shares

Expires not disclosed

F2 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001802768-25-000105 · wk-form4_1754686796.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 904,396

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0000950170-25-082342 · ownership.xml · derivative · entry 4

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 84,283,430

Underlying: Class A Ordinary Shares · 3,823,996 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (the "Common Units") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis.

F5 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F5 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-25-082342 · ownership.xml · derivative · entry 3

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 84,283,430

Underlying: Class A Ordinary Shares · 3,823,996 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (the "Common Units") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis.

F4 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F4 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-25-082342 · ownership.xml · nonDerivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 22,617,909

F2 · kind: Prior to June 3, 2025 (the "Transaction Date"), Tolerantia held 88,107,426 Common Units in ProKidney and an equal number of Class B Ordinary Shares (the "Paired Interests"), 84,160,537 of which were held by Nefro Health, an Irish partnership that is an affiliate controlled and majority-owned by Mr. Pablo Legorreta, and 3,946,889 of which were held by other investors which are unaffiliated with Mr. Legorreta (the "Unaffiliated Investors"). On the Transaction Date, Tolerantia exchanged 3,823,996 of the 3,946,889 Paired Interests attributable to the interests of the Unaffiliated Investors in Tolerantia for 3,823,996 Class A Ordinary Shares, which it subsequently distributed in-kind pro rata for no consideration to the Unaffiliated Investors.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-25-082342 · ownership.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 26,441,905

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-25-080277 · ownership.xml · derivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,862

Underlying: Class A Ordinary Shares · 125,862 shares

Expires 2035-05-29

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0001802768-25-000063 · wk-form4_1747774159.xml · derivative · entry 14

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Indirect · By PL RPH Holdings, LLC

Disclosed balance after: 857,138

Underlying: Class A Ordinary Shares · 857,138 shares

Expires not disclosed

F4 · shares: Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee.

F3 · derivative.exercise_date: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F4 · derivative.exercise_date: Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee.

F3 · derivative.expiration_date: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F4 · derivative.expiration_date: Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee.

F3 · derivative.underlying_shares: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F4 · balance_after: Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee.

F4 · ownership.nature: Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee.

SEC source: 0001802768-25-000063 · wk-form4_1747774159.xml · derivative · entry 13

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Indirect · By PL RPH Holdings, LLC

Disclosed balance after: 13,356,742

Underlying: Class A Ordinary Shares · 13,356,742 shares

Expires not disclosed

F2 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares ("Class E Shares") of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as may be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto.

F3 · derivative.exercise_date: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F3 · derivative.expiration_date: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F3 · derivative.underlying_shares: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F3 · balance_after: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F2 · ownership.nature: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares ("Class E Shares") of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as may be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto.

F3 · ownership.nature: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

SEC source: 0001802768-25-000063 · wk-form4_1747774159.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 882,495

F1 · kind: Represents the transfer to the Reporting Person by the RP Management Equity Incentive Plan Trust of Class A Ordinary Shares for no consideration.

SEC source: 0001802768-25-000043 · wk-form4_1747256539.xml · derivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 867,180 shares

Expires not disclosed

F1 · kind: Reflects an exempt gift for no consideration of Class B ordinary shares ("Class B Shares") of Royalty Pharma Holdings Ltd ("RPH") from the reporting person's spouse to the reporting person. The Class B Shares held by the reporting person's spouse were originally received in an exempt pro rata distribution pursuant to Rule 16a-9(a).

F2 · derivative.exercise_date: Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis (at which time, a corresponding number of Class B ordinary shares will also be forfeited and redesignated on a one-for-one basis), and there is no expiration date for such conversion.

F2 · derivative.expiration_date: Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis (at which time, a corresponding number of Class B ordinary shares will also be forfeited and redesignated on a one-for-one basis), and there is no expiration date for such conversion.

F3 · balance_after: Reflects the exempt transfer pursuant to Rule 16a-13 of Class B Shares from the reporting person and the GST-Exempt Legorreta 2020 Family Trust to PL RPH AIV, LLC, which is solely beneficially owned by the reporting person. The Class B Shares transferred by the reporting person and the GST-Exempt Legorreta 2020 Family Trust were originally received in exempt pro rata distributions pursuant to Rule 16a-9(a) and the gift transaction reported in this filing.

SEC source: 0001802768-25-000043 · wk-form4_1747256539.xml · derivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 867,180 shares

Expires not disclosed

F1 · kind: Reflects an exempt gift for no consideration of Class B ordinary shares ("Class B Shares") of Royalty Pharma Holdings Ltd ("RPH") from the reporting person's spouse to the reporting person. The Class B Shares held by the reporting person's spouse were originally received in an exempt pro rata distribution pursuant to Rule 16a-9(a).

F2 · derivative.exercise_date: Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis (at which time, a corresponding number of Class B ordinary shares will also be forfeited and redesignated on a one-for-one basis), and there is no expiration date for such conversion.

F2 · derivative.expiration_date: Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis (at which time, a corresponding number of Class B ordinary shares will also be forfeited and redesignated on a one-for-one basis), and there is no expiration date for such conversion.

SEC source: 0001802768-25-000039 · wk-form4_1746825503.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 352,147

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0000950170-25-015495 · ownership.xml · derivative · entry 4

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 88,107,426

Underlying: Class A Ordinary Shares · 532,535 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (the "Common Units") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis.

F5 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F5 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-25-015495 · ownership.xml · derivative · entry 3

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 88,107,426

Underlying: Class A Ordinary Shares · 532,535 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (the "Common Units") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis.

F4 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F4 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-25-015495 · ownership.xml · nonDerivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 22,617,909

F2 · kind: Prior to February 4, 2025 (the "Transaction Date"), Tolerantia held 88,639,961 Common Units in ProKidney and an equal number of Class B Ordinary Shares (the "Paired Interests"), 84,160,537 of which were held by Nefro Health, an Irish partnership that is an affiliate controlled and majority-owned by Mr. Pablo Legorreta, and 4,479,424 of which were held by other investors which are unaffiliated with Mr. Legorreta (the "Unaffiliated Investors"). On the Transaction Date, Tolerantia exchanged 532,535 of the 4,479,424 Paired Interests attributable to the interests of the Unaffiliated Investors in Tolerantia for 532,535 Class A Ordinary Shares, which it subsequently distributed in-kind pro rata for no consideration to the Unaffiliated Investors.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-25-015495 · ownership.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 23,150,444

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-24-073633 · ownership.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 22,617,909

F1 · ownership.nature: Represents equity interests held by or for the benefit of Tolerantia, LLC, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia, LLC. Mr. Legorreta disclaims beneficial ownership of the equity interests held by or for the benefit of Tolerantia, LLC except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-24-068045 · ownership.xml · derivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,558

Underlying: Class A Ordinary Shares · 62,558 shares

Expires 2034-05-30

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0000950170-24-011711 · ownership.xml · derivative · entry 4

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 88,639,961

Underlying: Class A Ordinary Shares · 748,952 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (the "Common Units") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis.

F5 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F5 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-24-011711 · ownership.xml · derivative · entry 3

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 88,639,961

Underlying: Class A Ordinary Shares · 748,952 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (the "Common Units") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis.

F4 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F4 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-24-011711 · ownership.xml · nonDerivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F2 · kind: Prior to February 5, 2024 (the "Transaction Date"), Tolerantia held 89,388,913 Common Units in ProKidney and an equal number of Class B Ordinary Shares (the "Paired Interests"), 84,160,537 of which were held by Nefro Health, an Irish partnership that is an affiliate controlled and majority-owned by Mr. Pablo Legorreta, and 5,228,376 of which were held by other investors which are unaffiliated with Mr. Legorreta (the "Unaffiliated Investors"). On the Transaction Date, Tolerantia exchanged 748,952 of the 5,228,376 Paired Interests attributable to the interests of the Unaffiliated Investors in Tolerantia for 748,952 Class A Ordinary Shares, which it subsequently distributed in-kind pro rata for no consideration to the Unaffiliated Investors.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-24-011711 · ownership.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 748,952

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950103-23-016404 · dp202859_4-legorreta.xml · nonDerivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,795

F1 · kind: Represents the transfer by the Reporting Person of Class A ordinary shares for no consideration to RP Management Equity Incentive Plan Trust.

F2 · balance_after: Reflects the exempt transfer pursuant to Rule 16a-13 of Class A ordinary shares from the GST-Exempt Legorreta 2012 Family Trust.

SEC source: 0001209191-23-054044 · doc4.xml · derivative · entry 4

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 89,388,913

Underlying: Class A Ordinary Shares · 5,289,055 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (the "Common Units") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis.

F5 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F5 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0001209191-23-054044 · doc4.xml · derivative · entry 3

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 89,388,913

Underlying: Class A Ordinary Shares · 5,289,055 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (the "Common Units") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis.

F4 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F4 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0001209191-23-054044 · doc4.xml · nonDerivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F2 · kind: Prior to October 30, 2023 (the "Transaction Date"), Tolerantia held 94,677,968 Common Units in ProKidney and an equal number of Class B Ordinary Shares (the "Paired Interests"), 84,160,537 of which were held by Nefro Health, an Irish partnership that is an affiliate controlled and majority-owned by Mr. Pablo Legorreta, and 10,517,431 of which were held by other investors which are unaffiliated with Mr. Legorreta (the "Unaffiliated Investors"). On the Transaction Date, Tolerantia exchanged 5,289,055 of the 10,517,431 Paired Interests attributable to the interests of the Unaffiliated Investors in Tolerantia for 5,289,055 Class A Ordinary Shares, which it subsequently distributed in-kind pro rata for no consideration to the Unaffiliated Investors.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0001209191-23-054044 · doc4.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 5,289,055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0001209191-23-040421 · doc4.xml · derivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,128

Underlying: Class A Ordinary Shares · 48,128 shares

Expires 2033-06-29

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0001209191-23-040024 · doc4.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Legorreta 2023 SR Trust

Disclosed balance after: 600,000

F1 · kind: Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program.

F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $29.40 to $29.60. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

SEC source: 0001209191-23-036624 · doc4.xml · nonDerivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Legorreta 2023 SR Trust

Disclosed balance after: 470,000

F1 · kind: Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program.

F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $32.66 to $32.80. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

SEC source: 0001209191-23-036624 · doc4.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Legorreta 2023 SR Trust

Disclosed balance after: 425,000

F1 · kind: Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program.

F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $32.97 to $33.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

SEC source: 0000950103-23-007785 · dp194284_4-legorreta.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Legorreta 2023 SR Trust

Disclosed balance after: 380,000

F1 · kind: Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program.

F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $32.20 to $32.28. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

SEC source: 0000950103-23-007427 · dp193902_4-legorreta.xml · nonDerivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Legorreta 2023 SR Trust

Disclosed balance after: 230,000

F1 · kind: Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program.

F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $32.70 to $33.28. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

SEC source: 0000950103-23-007427 · dp193902_4-legorreta.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Legorreta 2023 SR Trust

Disclosed balance after: 160,388

F1 · kind: Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program.

F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $33.48 to $33.76. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

SEC source: 0000950103-23-007321 · dp193834_4-legoretta.xml · derivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 692,701

Underlying: Limited Partnership interests in RPI US Partners 2019, LP · 10,269 shares

Expires not disclosed

F1 · kind: Reflects an exempt gift for no consideration of ICAI Interests from the reporting person's spouse to the reporting person.

F2 · derivative.exercise_date: These ICAI Interests represent a beneficial interest in an equivalent number of limited partnership interests ("RPI US LP Interests") in RPI US Partners 2019, LP ("RPI US LP") and may be exchanged into RPI US LP Interests on a one-for-one basis currently. The ICAI Interests do not have an expiration date.

F2 · derivative.expiration_date: These ICAI Interests represent a beneficial interest in an equivalent number of limited partnership interests ("RPI US LP Interests") in RPI US Partners 2019, LP ("RPI US LP") and may be exchanged into RPI US LP Interests on a one-for-one basis currently. The ICAI Interests do not have an expiration date.

F3 · derivative.underlying: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.

F4 · balance_after: Reflects the exempt change in the form of beneficial ownership without a change in the reporting person's pecuniary interest pursuant to Rule 16a-13 of certain ICAI Interests from being directly or indirectly owned by the reporting person through Legorreta Investments II LLC to being directly owned or indirectly owned through Legorreta Investments LLC and the reporting person's spouse.

SEC source: 0000950103-23-007321 · dp193834_4-legoretta.xml · derivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 0

Underlying: Limited Partnership interests in RPI US Partners 2019, LP · 10,269 shares

Expires not disclosed

F1 · kind: Reflects an exempt gift for no consideration of ICAI Interests from the reporting person's spouse to the reporting person.

F2 · derivative.exercise_date: These ICAI Interests represent a beneficial interest in an equivalent number of limited partnership interests ("RPI US LP Interests") in RPI US Partners 2019, LP ("RPI US LP") and may be exchanged into RPI US LP Interests on a one-for-one basis currently. The ICAI Interests do not have an expiration date.

F2 · derivative.expiration_date: These ICAI Interests represent a beneficial interest in an equivalent number of limited partnership interests ("RPI US LP Interests") in RPI US Partners 2019, LP ("RPI US LP") and may be exchanged into RPI US LP Interests on a one-for-one basis currently. The ICAI Interests do not have an expiration date.

F3 · derivative.underlying: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.

F4 · balance_after: Reflects the exempt change in the form of beneficial ownership without a change in the reporting person's pecuniary interest pursuant to Rule 16a-13 of certain ICAI Interests from being directly or indirectly owned by the reporting person through Legorreta Investments II LLC to being directly owned or indirectly owned through Legorreta Investments LLC and the reporting person's spouse.

SEC source: 0000950103-23-016404 · dp202859_4-legorreta.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Tata MC 35 Ltd.

Disclosed balance after: 292,190.49

SEC source: 0000899243-22-028860 · doc4.xml · derivative · entry 3

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

RP Management, LLC · CIK 0001507673 · Director · 10% owner

RPI Finance Trust · CIK 0001793690 · Director · 10% owner

Royalty Pharma Investments 2019 ICAV · CIK 0001909645 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,994 shares

Expires not disclosed

F7 · derivative.exercise_date: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

F7 · derivative.expiration_date: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

F5 · ownership.direct: Mr. Legorreta is deemed to hold the derivative security and the shares issuable thereunder for the benefit of RP Management. Mr. Legorreta is the manager of RP Management. Any exercise of the derivative security, when vested, or sale of the shares issuable upon exercise shall be at the direction of RP Management and the proceeds of the sale of the shares issuable upon exercise shall be delivered to RP Management. The proceeds of the sale of the shares issuable under the derivative security will be offset against the management fee payable to RP Management by RPIFT, RPI 2019 ICAV, and certain of their respective indirect owners (such indirect owners, the "Funds"), all of which are managed by RP Management.

F6 · ownership.direct: (Continued from Footnote 5) Mr. Legorreta and such Funds disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that Mr. Legorreta or any of such Funds is the beneficial owner thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta served on the board of directors of the Issuer as a representative of RPIFT and RPI 2019 ICAV. Each of RPIFT, RPI 2019 ICAV and RP Management may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act.

SEC source: 0000899243-22-028860 · doc4.xml · derivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

RP Management, LLC · CIK 0001507673 · Director · 10% owner

RPI Finance Trust · CIK 0001793690 · Director · 10% owner

Royalty Pharma Investments 2019 ICAV · CIK 0001909645 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,060 shares

Expires not disclosed

F7 · derivative.exercise_date: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

F7 · derivative.expiration_date: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

F5 · ownership.direct: Mr. Legorreta is deemed to hold the derivative security and the shares issuable thereunder for the benefit of RP Management. Mr. Legorreta is the manager of RP Management. Any exercise of the derivative security, when vested, or sale of the shares issuable upon exercise shall be at the direction of RP Management and the proceeds of the sale of the shares issuable upon exercise shall be delivered to RP Management. The proceeds of the sale of the shares issuable under the derivative security will be offset against the management fee payable to RP Management by RPIFT, RPI 2019 ICAV, and certain of their respective indirect owners (such indirect owners, the "Funds"), all of which are managed by RP Management.

F6 · ownership.direct: (Continued from Footnote 5) Mr. Legorreta and such Funds disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that Mr. Legorreta or any of such Funds is the beneficial owner thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta served on the board of directors of the Issuer as a representative of RPIFT and RPI 2019 ICAV. Each of RPIFT, RPI 2019 ICAV and RP Management may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act.

SEC source: 0000899243-22-028860 · doc4.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

RP Management, LLC · CIK 0001507673 · Director · 10% owner

RPI Finance Trust · CIK 0001793690 · Director · 10% owner

Royalty Pharma Investments 2019 ICAV · CIK 0001909645 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

F1 · shares: Represents (a) (i) 6,666,667 shares of the Issuer's common stock ("Shares") and (ii) 2,500,000 shares of the Issuer's common stock, in each case acquired by RPI Finance Trust ("RPIFT") pursuant to that certain Purchase Agreement, dated November 4, 2019, by and between the Issuer and RPIFT and (b) 22,666,667 shares of common stock acquired by Royalty Pharma Investments 2019 ICAV ("RPI 2019 ICAV") from the underwriter in an underwritten public offering conducted by the Issuer that closed on January 31, 2022.

F2 · shares: Reflects disposition of Shares in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.

F2 · price: Reflects disposition of Shares in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.

F3 · ownership.nature: This Form 4 is being jointly filed by RP Management, LLC ("RP Management"), RPIFT, and Pablo G. Legorreta (collectively, the "Reporting Persons"). RP Management, as the manager of RPIFT and RPI 2019 ICAV, and Mr. Legorreta, as the manager of RP Management, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") of the securities beneficially owned by RPIFT and RPI 2019 ICAV. RP Management and Mr. Legorreta disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that RP Management and/or Mr. Legorreta are the beneficial owners thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta served on the board of directors of the Issuer as a representative of RPIFT and RPI 2019 ICAV.

F4 · ownership.nature: (Continued from Footnote 3) Each of RPIFT, RPI 2019 ICAV and RP Management, LLC may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act.

SEC source: 0001209191-23-008556 · doc5.xml · derivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Legorreta Investments LLC

Disclosed balance after: 2,700,000

Underlying: Class A Ordinary Shares · 1,506,400 shares

Expires not disclosed

F1 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.

F2 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F4 · balance_after: The Reporting Person has agreed to retain and not sell 5,103,392 RPI US LP Interests convertible into 51,033,928 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

SEC source: 0000950103-22-012372 · dp177035_4-legorreta.xml · derivative · entry 3

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 10,500,000

Underlying: Class A Ordinary Shares · 10,500,000 shares

Expires not disclosed

F7 · derivative.exercise_price: The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons.

F7 · shares: The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons.

F8 · shares: One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the Closing.

F7 · derivative.exercise_date: The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons.

F7 · derivative.expiration_date: The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons.

F7 · derivative.underlying_shares: The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons.

F8 · derivative.underlying_shares: One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the Closing.

F2 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legoretta. Mr. Legoretta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950103-22-012372 · dp177035_4-legorreta.xml · derivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 94,677,968

Underlying: Class A Ordinary Shares · 94,677,968 shares

Expires not disclosed

F5 · derivative.exercise_price: Each Common Unit may, at the election of the reporting persons and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis.

F6 · derivative.exercise_price: 91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire.

F6 · shares: 91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire.

F6 · derivative.exercise_date: 91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire.

F6 · derivative.expiration_date: 91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire.

F6 · derivative.underlying_shares: 91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire.

F6 · balance_after: 91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire.

F2 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legoretta. Mr. Legoretta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.